Milestone Pharmaceuticals Inc
MIST1.495USD
+0.065+4.55%
Market hours （ET）Quotes delayed by 15 min
79.93MMarket Cap
LossP/E TTM
More Details of Milestone Pharmaceuticals Inc Company
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Company Info
Ticker SymbolMIST
Company nameMilestone Pharmaceuticals Inc
IPO dateMay 09, 2019
CEOMr. Joseph Oliveto
Number of employees33
Security typeOrdinary Share
Fiscal year-endMay 09
Address420-1111 boul. Dr.-Frederik-Philips
CityMONTREAL
Stock exchangeNASDAQ Global Select Consolidated
CountryCanada
Postal codeH4M 2X6
Phone15143360444
Websitehttps://www.milestonepharma.com
Ticker SymbolMIST
IPO dateMay 09, 2019
CEOMr. Joseph Oliveto
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 26
Updated: Sat, Jul 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Trails Edge Capital Partners LP
6.28%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
1.71%
Alta Fundamental Advisers LLC
1.68%
Other
84.43%
Shareholders
Shareholders
Proportion
Trails Edge Capital Partners LP
6.28%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
1.71%
Alta Fundamental Advisers LLC
1.68%
Other
84.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.84%
Individual Investor
3.61%
Investment Advisor/Hedge Fund
3.37%
Hedge Fund
2.90%
Research Firm
2.38%
Venture Capital
1.77%
Bank and Trust
0.03%
Other
76.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
98
14.43M
18.73%
-14.88M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
2023Q1
110
22.19M
66.58%
-11.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Oliveto (Joseph Gerard)
2.44M
4.57%
+2.16M
+756.94%
Apr 15, 2025
RTW Investments L.P.
2.51M
4.69%
--
--
Mar 31, 2025
Propel Bio Management, LLC
1.45M
2.71%
+1.25M
+625.78%
Mar 31, 2025
Alta Fundamental Advisers LLC
1.43M
2.67%
-1.23M
-46.31%
Mar 31, 2025
BML Capital Management LLC
1.14M
2.13%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
965.92K
1.81%
-320.62K
-24.92%
Mar 31, 2025
Simplify Asset Management Inc
850.00K
1.59%
+850.00K
--
Mar 31, 2025
TD Securities, Inc.
750.00K
1.4%
--
--
Mar 31, 2025
Lion Point Capital, L.P.
548.81K
1.03%
-477.00K
-46.50%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Simplify Propel Opportunities ETF
2.84%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
Proportion2.84%
SPDR S&P International Small Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
